This study is the first to report on the high expression of the LDHAP5 pseudogene in ovarian serous cystadenocarcinoma, which may lead to poor prognosis via its targeting of EGFR. Thus, LDHAP5 may serve as a new therapeutic target, and improve the prognosis of patients with ovarian cancer in the future. This evidence concerns the gene LDHAP5 and ovarian cancer.